Overview

RCT Cefiderocol vs BAT for Treatment of Gram Negative BSI

Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether a new antibiotic, Cefiderocol which works against a wide variety of gram negative bacteria, is equally effective as the antibiotics that are currently used as current standard of care.
Phase:
Phase 2
Details
Lead Sponsor:
The University of Queensland
Collaborator:
Shionogi
Treatments:
Cephalosporins